E
Eliezer J. Barreiro
Researcher at Federal University of Rio de Janeiro
Publications - 356
Citations - 10647
Eliezer J. Barreiro is an academic researcher from Federal University of Rio de Janeiro. The author has contributed to research in topics: Pyrazole & Docking (molecular). The author has an hindex of 45, co-authored 348 publications receiving 9164 citations. Previous affiliations of Eliezer J. Barreiro include Centre national de la recherche scientifique & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Molecular hybridization: A useful tool in the design of new drug prototypes
Claudio Viegas-Junior,Amanda Danuello,Vanderlan da Silva Bolzani,Eliezer J. Barreiro,Carlos A. M. Fraga +4 more
TL;DR: Several examples of different strategies for drug design, discovery and pharmacomodulation focused on new innovative hybrid compounds presenting analgesic,Anti-inflammatory, platelet anti-aggregating, anti-infectious, anticancer, cardio- and neuroactive properties are described.
Journal ArticleDOI
Bioisosterism: a useful strategy for molecular modification and drug design.
TL;DR: This review aim to demonstrate the role of bioisosterism in rational drug design as well as in the molecular modification and optimization process aiming to improve pharmacodynamic and pharmacokinetic properties of lead compounds.
Journal ArticleDOI
The methylation effect in medicinal chemistry.
TL;DR: The Methylation Effect in Medicinal Chemistry Eliezer J. Barreiro,* Arthur E. K€ummerle, and Carlos A. M. Fraga Laborat orio de Avaliac-~ao e Síntese de Subst̂ancias Bioativas (LASSBio), Faculdade de Farm acia, Universidade Federal do Rio de Janeiro, CCS, Cidade Universit aria.
Journal ArticleDOI
From nature to drug discovery: the indole scaffold as a 'privileged structure'.
TL;DR: The indole scaffold probably represents one of the most important structural subunits for the discovery of new drug candidates, explaining the great number of drugs that contain the indole substructure, such as indomethacin, ergotamine, frovatriptan, ondansetron, tadalafil, among many others.
Journal ArticleDOI
Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
TL;DR: The development of antineoplastic ruthenium therapeutic complexes NAMI-A, KP1019, and KP1339 entered clinical trials and DW1/2 is in preclinical levels, and the very robust, conformationally rigid organometallic Ru(II) compound DW1 /2 is a protein kinase inhibitor and presents new Ru( II) compound designs as anticancer agents.